Earnings call Akebia delivered strong Vafseo growth in Q1 2026, with net product revenue up 32% YoY to $15.8M and a 60% sequential increase in patients on therapy, offsetting AURYXIA declines from ...
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
Akebia Therapeutics Inc. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is ...
Chart does not reflect overnight price.
Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results